Our top pick for
Crescent Acquisition Corp is a shell companies business based in the US. Crescent Acquisition shares (CRSA) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$9.1 - USD$12|
|50-day moving average||USD$10.3947|
|200-day moving average||USD$10.2182|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.013|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Crescent Acquisition stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Crescent Acquisition's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Crescent Acquisition's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 779x. In other words, Crescent Acquisition shares trade at around 779x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-0.22%|
|Return on equity TTM||8.29%|
|Market capitalisation||USD$316.6 million|
TTM: trailing 12 months
There are currently 301,181 Crescent Acquisition shares held short by investors – that's known as Crescent Acquisition's "short interest". This figure is 4.6% down from 315,599 last month.
There are a few different ways that this level of interest in shorting Crescent Acquisition shares can be evaluated.
Crescent Acquisition's "short interest ratio" (SIR) is the quantity of Crescent Acquisition shares currently shorted divided by the average quantity of Crescent Acquisition shares traded daily (recently around 1.6 million). Crescent Acquisition's SIR currently stands at 0.19. In other words for every 100,000 Crescent Acquisition shares traded daily on the market, roughly 190 shares are currently held short.
However Crescent Acquisition's short interest can also be evaluated against the total number of Crescent Acquisition shares, or, against the total number of tradable Crescent Acquisition shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crescent Acquisition's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Crescent Acquisition shares in existence, roughly 10 shares are currently held short) or 0.014% of the tradable shares (for every 100,000 tradable Crescent Acquisition shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Crescent Acquisition.
Find out more about how you can short Crescent Acquisition stock.
We're not expecting Crescent Acquisition to pay a dividend over the next 12 months.
Crescent Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or business combination. The company was formerly known as Crescent Funding Inc. and changed its name to Crescent Acquisition Corp. in October 2018. The company was founded in 2017 and is based in Los Angeles, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.